PROTOCOL SPECIFIC MATERIALS
PROTOCOL GOG 0233/ACRIN 6671

Utility of Preoperative FDG-PET/CT Prior to Primary Chemoradiation Therapy
to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally
Advanced Carcinoma of the Cervix
(IB2, IIA =4 CM, IIB-IVA) or Endometrium
(Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear
Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 or 2 Endometrioid
Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical
Examination or Confirmed by Endocervical Curettage)

Protocol Documents 

Protocol-GOG 0233/ACRIN 6671 Amendment 11, 6.25.12 (effective 6.25.12) [PDF]

SOC-GOG 0233/ACRIN 6671 Amendment 11, 6.25.12 (effective 6.25.12) [PDF]

Informed Consent-GOG 0233/ACRIN 6671 [DOC]

Principal Investigator: Mostafa Atri, MD, ACRIN Principal Investigator
                                      Michael Gold, MD, GOG Study Chair

Status: In Analysis

Primary Objectives: 

  • To evaluate the diagnostic sensitivity and specificity of preoperative
    FDG-PET/CT imaging in identifying metastases to abdominal (common
    iliac, para-aortic, and para-caval) lymph nodes in patients with locoregionally
    advanced cervical carcinoma.
  • To evaluate the diagnostic sensitivity and specificity of preoperative
    FDG-PET/CT imaging in identifying metastases to retroperitoneal abdominal
    lymph nodes in patients with high-risk endometrial carcinoma.

Participants:  Participating women must have either: primary, previously untreated,
histologically confirmed, locoregionally advanced (IB2, IIA ≥4cm, IIB-IVA) invasive
carcinoma of the cervix (any cell type) AND must be appropriate surgical candidates
to undergo extra-peritoneal or laparoscopic lymph node sampling OR histologically
confirmed Grade 3 endometrioid or non-endometrioid endometrial carcinoma (clear
cell or serous papillary) or carcinosarcoma as diagnosed from an endometrial biopsy
or dilation and curettage or histologically confirmed Grade 1 or 2 endometrioid
endometrial carcinoma with cervical stromal involvement overt on clinical examination
or confirmed by endocervical curettage AND must be appropriate surgical candidates
to undergo hysterectomy and lymph node sampling.